Health-Related Quality-of-Life Improvements after Exagamglogene Autotemcel in Patients with Severe Sickle Cell Disease
Akshay Sharma(St. Jude Children's Research Hospital), Stephan A. Grupp(Children's Hospital of Philadelphia), Haydar Frangoul(Children’s Hospital at TriStar Centennial), Franco Locatelli(Bambino Gesù Children's Hospital), Monica Bhatia(Columbia University Irving Medical Center), Jaime Rubin(Vertex Pharmaceuticals (United States)), Kevin H.M. Kuo(University Health Network), Michael J. Eckrich(Levine Children's Hospital), Tina Liu, Suzan Imren(Fred Hutch Cancer Center), William Hobbs(Vertex Pharmaceuticals (United States)), Markus Y. Mapara(Sheba Medical Center), Siyu Zhang(Xi'an Jiaotong University), Nanxin Li(Genomics Institute of the Novartis Research Foundation)
Cited by 1
Related Papers
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
|Nature|2012|8.5k
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia
|New England Journal of Medicine|2020|1.8k